Premium
Survival after secondary cytoreduction for recurrent ovarian cancer: Which are the prognostic factors?
Author(s) -
Biliatis Ioannis,
Haidopoulos Dimitrios,
Rodolakis Alexandros,
Vlachos Georgios,
Protopapas Athanasios,
Thomakos Nikolaos,
Sergentanis Theodoros,
Akrivos Nikolaos,
Antsaklis Aris
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21686
Subject(s) - medicine , ovarian cancer , proportional hazards model , stage (stratigraphy) , chemotherapy , cancer , survival analysis , oncology , paclitaxel , surgery , overall survival , disease , paleontology , biology
Objective Significant controversy exists concerning the factors affecting survival after secondary cytoreduction (SCR) in recurrent ovarian cancer. This study aims to identify factors independently associated with survival after SCR. Methods We retrospectively retrieved 39 patients with recurrent ovarian cancer. All patients had been initially treated with primary cytoreduction in our institution and received platinum‐ and paclitaxel‐based chemotherapy postoperatively. Disease‐free interval (DFI) had to be longer than 6 months. A variety of clinicopathological factors were recorded. Multivariable Cox regression was performed to examine the associations of parameters with survival. Results Median survival was equal to 24 months, the median DFI was 22 months, and complete SCR had been achieved in 19/39 patients (48.7%, 95% CI: 32.4–65.2%). Higher number of recurrence sites, clear‐cell histological type, and more advanced FIGO stage were independently associated with shorter survival; longer DFI was associated with longer survival. Noticeably, complete SCR lost its significance at the multivariable model, although it was associated with longer survival at the univariable analysis. Conclusions Four factors seem capable of independently modifying survival after SCR: number of recurrence sites, DFI, FIGO stage, and clear cell histology. The two latter factors might reflect aggressive clinicopathological features of the tumor with long‐term effect. J. Surg. Oncol. 2010;102:671–675. © 2010 Wiley‐Liss, Inc.